PRA News & Events

Reports Q4 revenue $201.52M, consensus $261.08M. "We continue to see progress toward our objectives," said Ned Rand, President and CEO of ProAssurance. "Joining forces with The Doctors Company through the transaction we announced in March 2025 will allow our organizations to continue to serve today's healthcare providers with the necessary scale and breadth of capabilities.

Reports Q3 revenue $279.55M, consenesus $268.71M. "Our history in medical professional liability has taught us that our focused efforts will be successful over the long-term in this cyclical market and we are pleased with the progress we continue to see," said Ned Rand, President and Chief Executive Officer of ProAssurance. "Joining forces with The Doctors Company through the transaction we announced in March will allow our organizations to continue to serve today's healthcare providers with the necessary scale and breadth of capabilities."

Reports Q2 revenue $276.8M, consensus $265.8M. The company said, "The quarter again illustrated benefits from our focus on ongoing actions to achieve sustained profitability, including price adequacy, disciplined underwriting and cost management, and we expect to see further progress in coming quarters. Joining forces with The Doctors Company through the transaction we announced in March will allow our organizations to continue to serve today's healthcare providers with the necessary scale and breadth of capabilities. On June 24, ProAssurance stockholders overwhelmingly approved the transaction, and on July 2 the Federal Trade Commission granted the transaction early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction remains subject to regulatory approvals by the insurance regulators in the domicile states (and District of Columbia) of ProAssurance's insurance subsidiaries as well as other customary closing conditions, and is expected to close in the first half of 2026."

ProAssurance Corporation announced that stockholders have voted overwhelmingly to approve its proposed acquisition by The Doctors Company. More than 99% of shares voted were in favor of the proposal to approve the acquisition agreement. The transaction remains subject to the receipt of regulatory approvals and other customary closing conditions and is expected to close in the first half of 2026. Required regulatory approvals include the expiration or early termination of the waiting period applicable to the consummation of the merger under the Hart-Scott-Rodino Act as well as approvals by the insurance regulators in the domicile states of ProAssurance insurance subsidiaries. The transaction is not subject to a financing condition. Upon completion of the transaction, ProAssurance's common stock will no longer be listed on the New York Stock Exchange, and ProAssurance will become a wholly owned subsidiary of The Doctors Company. "Our shareholders recognize that this transaction will deliver significant value," said Ned Rand, ProAssurance's President and Chief Executive Officer. He added, "Bringing the strengths and capabilities of ProAssurance and The Doctors Company together will allow our teams to continue to serve today's healthcare providers with the necessary scale and breadth of capabilities. With a shared history in the medical professional liability marketplace, both companies work to fulfill a mission to protect others and have similar operating philosophies and cultures."